Evidence map›Paper›PMID 36865264›Full record

ArticlebioRxiv : the preprint server for biology2023

Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes.

Justin A Spanier, Vivian Fung, Christine M Wardell, Mohannad H Alkhatib, Yixin Chen, Linnea A Swanson, Alexander J Dwyer, Matthew E Weno, Nubia Silva, Jason S Mitchell and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Justin A SpanierCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Vivian FungDept of Surgery, University of British Columbia, Vancouver, BC, Canada.
Christine M WardellDept of Surgery, University of British Columbia, Vancouver, BC, Canada.
Mohannad H AlkhatibCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Yixin ChenCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Linnea A SwansonDepartment of Medicine, Division of Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, USA.
Alexander J DwyerCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Matthew E WenoCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Nubia SilvaCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Jason S MitchellCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.
Paul C OrbanDept of Surgery, University of British Columbia, Vancouver, BC, Canada.
Majid MojibianDept of Surgery, University of British Columbia, Vancouver, BC, Canada.
C Bruce VerchereDept of Surgery, University of British Columbia, Vancouver, BC, Canada.
Brian T FifeCenter for Immunology, University of Minnesota Medical School, Minneapolis, MN, USA.ORCID 0000-0001-9826-5637
Megan K LevingsDept of Surgery, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-0305-5790
University of Minnesota · USUniversity of British Columbia · CAUniversity of Minnesota Medical Center · US

Funding

Type I interferons in tolerance in the steady stateP01AI035296 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MUELLER, DANIEL L · 1993 to 2023
$31.1M
Identifying and preventing antigen specific T cells in diabetesR01AI156276 · NIAID · UNIVERSITY OF MINNESOTA · PI FIFE, BRIAN T · 2021 to 2025
$3.0M
Engineering CAR Tregs for type 1 diabetesR21AI166475 · NIAID · UNIVERSITY OF MINNESOTA · PI FIFE, BRIAN T · 2021 to 2022
$424k
Medical Student Summer Research Program in Infection and ImmunityT35AI118620 · NIAID · UNIVERSITY OF MINNESOTA · PI MUELLER, DANIEL L · 2015 to 2025
$351k
NIAID NIH HHS P01 AI035296NIAID NIH HHS R01 AI156276NIAID NIH HHS R21 AI166475NIAID NIH HHS T35 AI118620
6 · The paper itself

Abstract

Adoptive immunotherapy with Tregs is a promising approach for prevention or treatment of type 1 diabetes. Islet antigen-specific Tregs have more potent therapeutic effects than polyclonal cells, but their low frequency is a barrier for clinical application. To generate Tregs that recognize islet antigens, we engineered a chimeric antigen receptor (CAR) derived from a monoclonal antibody with specificity for the insulin B-chain 10-23 peptide presented in the context of the IA Brief Summary: Chimeric antigen receptor Tregs specific for an insulin B-chain peptide presented by MHC class II prevent autoimmune diabetes.

Identifiers

PMID36865264
PMCPMC9980092
OpenAlexW4321765143

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.